Gross Profit Analysis: Comparing Vericel Corporation and Taro Pharmaceutical Industries Ltd.

Vericel's growth outpaces Taro's decline in gross profit.

__timestampTaro Pharmaceutical Industries Ltd.Vericel Corporation
Wednesday, January 1, 201458000600011503000
Thursday, January 1, 201567658500024698000
Friday, January 1, 201677896600026076000
Sunday, January 1, 201767125100033570000
Monday, January 1, 201846350800058697000
Tuesday, January 1, 201944572400080279000
Wednesday, January 1, 202039972500084228000
Friday, January 1, 2021296656000106025000
Saturday, January 1, 2022293122000109788000
Sunday, January 1, 2023268323000135576000
Monday, January 1, 2024304979000
ngram

Gross Profit Trends: Vericel vs. Taro Pharmaceutical

In the ever-evolving pharmaceutical landscape, understanding financial health is crucial. This analysis delves into the gross profit trends of Vericel Corporation and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Taro, a stalwart in the industry, saw its gross profit peak in 2016, with a notable decline of approximately 65% by 2023. Meanwhile, Vericel, a rising star, showcased a remarkable growth trajectory, with its gross profit increasing nearly twelvefold over the same period.

Key Insights

  • Taro's Decline: Taro's gross profit dropped from its 2016 high, reflecting industry challenges and market dynamics.
  • Vericel's Surge: Vericel's consistent growth highlights its strategic advancements and market penetration.

These trends underscore the dynamic nature of the pharmaceutical sector, where innovation and adaptability are key to sustaining financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025